Company: DVAX
Filing Date: 2025-02-19
Form Type: DFAN14A
Source: 0001193125-25-029690
Chunk: 8

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-02-19
Form: DFAN14A
Chunk 8
---
 Farrow: the Chief Financial Officer at Tarsus Pharmaceuticals (NASDAQ: TARS). Mr. Farrow                                                                                                                                                      
 was also the CFO at Global Blood Therapeutics, Inc. (formerly NASDAQ: GBT; sold to Pfizer for $5.4 billion), ZS Pharma, Inc. (formerly NASDAQ: ZSPH; sold to AstraZeneca for $2.7 billion), and Hyperion Therapeutics (formerly NASDAQ: HPTX; sold to 
 Horizon Pharma plc for $1.1 billion).                                                                                                                                                                                                                 |

| 3. | Michael Mullette: the interim Chief Executive Officer at Lykos Therapeutics. Mr. Mullette was                                                                                                                                                 
 previously the Vice President of North American Commercial Operations at Moderna, Inc. (NASDAQ: MRNA) and spent nearly twenty years at Sanofi (NASDAQ: SNY) in a variety of positions including senior roles in global commercial operations. |

| 4. | Donald Santel: the former President and Chief Executive Officer of Hyperion Therapeutics (formerly                                                                                                                                              
 NASDAQ: HPTX), which developed and brought Ravicti to market for urea cycle disorders and was ultimately acquired by Horizon Pharma in 2015. Prior to Hyperion, Mr. Santel was the Chief Executive Officer of CoTherix (formerly NASDAQ: CTRX), 
 which developed Ventavis for pulmonary arterial hypertension and was acquired by Actelion in 2006.                                                                                                                                              |

Fortunately, shareholders can make their voices heard at the upcoming Annual Meeting. Dynavax deserves better than the status quo, and shareholders can be assured that our nominees will put shareholder interests first. Our interests have always been – and continue to be – directly aligned with those of all shareholders. We look forward to communicating further in the weeks to come. Regards, David Kroin Founder and Chief Investment Officer, Deep Track Capital LP APPENDIX: NOMINEE BIOGRAPHIES Brett Erkman Since October 2022, Brett Erkman has served as a Managing Director of Deep Track Capital, an investment firm focused on the life sciences. Prior to Deep Track, he was a biotechnology investor at Great Point Partners from October 2006 through April 2022. Previously, Mr. Erkman was a sell side associate at ThinkEquity Partners and a financial analyst at Abbott Laboratories. Mr. Erkman holds a B.S. in Finance from DePaul University. Jeffrey Farrow Jeffrey Farrow has served as Chief Financial Officer and Chief Strategy Officer of Tars